FDA Aligns with Vera Therapeutics on Accelerated Atacicept Approval Pathway
Summary
Vera Therapeutics announced FDA alignment on an accelerated timeline for atacicept's eGFR results and sBLA submission, moving up potential full approval for its IgA Nephropathy treatment.
Key Events
-
FDA Alignment for Atacicept
Vera Therapeutics has aligned with the U.S. Food and Drug Administration (FDA) on a revised, earlier ORIGIN 3 eGFR analysis plan for atacicept in adults with IgA Nephropathy.
-
Accelerated Timeline for Results
The eGFR results are now expected in the third quarter of 2026, an earlier timeline than previously anticipated.
-
Path to Full Approval
Pending these results, the company plans to submit a supplemental Biologics License Application (sBLA) for full approval of atacicept in the fourth quarter of 2026.
Analysis
Vera Therapeutics has secured alignment with the FDA on an earlier analysis plan for atacicept's ORIGIN 3 eGFR results, which are now expected in Q3 2026. This accelerates the potential submission of a supplemental Biologics License Application for full approval in Q4 2026, providing a clearer and faster path to market for its key IgA Nephropathy drug. This positive regulatory update for a lead candidate is a significant development for the company.
At the time of this filing, VERA was trading at $34.31 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.4B. The 52-week trading range was $18.79 to $56.05. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.